AU2013334860B2 - Compositions and methods for treating or preventing diseases or disorders associated with misregulated elF4E - Google Patents
Compositions and methods for treating or preventing diseases or disorders associated with misregulated elF4E Download PDFInfo
- Publication number
- AU2013334860B2 AU2013334860B2 AU2013334860A AU2013334860A AU2013334860B2 AU 2013334860 B2 AU2013334860 B2 AU 2013334860B2 AU 2013334860 A AU2013334860 A AU 2013334860A AU 2013334860 A AU2013334860 A AU 2013334860A AU 2013334860 B2 AU2013334860 B2 AU 2013334860B2
- Authority
- AU
- Australia
- Prior art keywords
- pct
- disease
- compound
- disorder
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 Cc(c1c2ccc(I)c1)n[n]2-c1nc(*)c(*)[s]1 Chemical compound Cc(c1c2ccc(I)c1)n[n]2-c1nc(*)c(*)[s]1 0.000 description 8
- FFDGPVCHZBVARC-UHFFFAOYSA-N CN(C)CC(O)=O Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- QHTUMQYGZQYEOZ-UHFFFAOYSA-N CN1CCN(CCO)CC1 Chemical compound CN1CCN(CCO)CC1 QHTUMQYGZQYEOZ-UHFFFAOYSA-N 0.000 description 1
- BMXHPMQKEMARLG-UHFFFAOYSA-N [O-][N+](c1ccccc1-c(ccc(-c1nc(-c(cc2)cc(Cl)c2Cl)c[s]1)c1)c1C(O)=O)=O Chemical compound [O-][N+](c1ccccc1-c(ccc(-c1nc(-c(cc2)cc(Cl)c2Cl)c[s]1)c1)c1C(O)=O)=O BMXHPMQKEMARLG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716987P | 2012-10-22 | 2012-10-22 | |
| US61/716,987 | 2012-10-22 | ||
| US201261735458P | 2012-12-10 | 2012-12-10 | |
| US61/735,458 | 2012-12-10 | ||
| PCT/US2013/066041 WO2014066304A1 (en) | 2012-10-22 | 2013-10-22 | Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013334860A1 AU2013334860A1 (en) | 2015-05-14 |
| AU2013334860B2 true AU2013334860B2 (en) | 2018-02-15 |
Family
ID=50545165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013334860A Ceased AU2013334860B2 (en) | 2012-10-22 | 2013-10-22 | Compositions and methods for treating or preventing diseases or disorders associated with misregulated elF4E |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9409901B2 (enExample) |
| EP (1) | EP2909203A4 (enExample) |
| JP (1) | JP2015534990A (enExample) |
| AU (1) | AU2013334860B2 (enExample) |
| CA (1) | CA2888889A1 (enExample) |
| IL (1) | IL238415B (enExample) |
| WO (1) | WO2014066304A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017015456A (es) * | 2015-06-01 | 2018-11-29 | Bantam Pharmaceutical Llc | Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos. |
| MX2019006296A (es) | 2016-11-30 | 2019-11-12 | Bantam Pharmaceutical Llc | Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. |
| WO2018102453A1 (en) * | 2016-11-30 | 2018-06-07 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| US12570975B2 (en) * | 2019-09-03 | 2026-03-10 | Sovargen Co., Ltd. | Composition for diagnosis or treatment of a condition associated with increased activity of EIF4E comprising an EIF4E inhibitor |
| WO2021067752A1 (en) * | 2019-10-04 | 2021-04-08 | Yale University | Targeting cap-dependent translation to reduce seizures in mtor disorders |
| MX2022010944A (es) * | 2020-03-03 | 2022-11-09 | Pic Therapeutics Inc | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008006790A1 (en) * | 2006-07-14 | 2008-01-17 | Glaxo Group Limited | Indole compounds |
| WO2008006793A1 (en) * | 2006-07-14 | 2008-01-17 | Glaxo Group Limited | Indole compounds |
| WO2012006068A2 (en) * | 2010-06-28 | 2012-01-12 | President And Fellows Of Harvard College | Compounds for the inhibition of cellular proliferation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| MXPA06012130A (es) * | 2004-04-20 | 2007-01-31 | Transtech Pharma Inc | Derivados de tiazol y pirimidina substituidos como moduladores del receptor de melanocortina. |
| US8257931B2 (en) * | 2005-01-21 | 2012-09-04 | President And Fellows Of Harvard College | Regulation of protein synthesis |
| AR063531A1 (es) * | 2006-10-31 | 2009-01-28 | Schering Corp | Derivados de anilinopiperazina y composicion farmaceutica |
| RU2010106878A (ru) * | 2007-07-31 | 2011-09-10 | Шеринг Корпорейшн (US) | Комбинация антимитотического агента и ингибитора аврора киназы как средство для лечения рака |
-
2013
- 2013-10-22 CA CA2888889A patent/CA2888889A1/en not_active Abandoned
- 2013-10-22 EP EP13849178.2A patent/EP2909203A4/en not_active Withdrawn
- 2013-10-22 JP JP2015538124A patent/JP2015534990A/ja active Pending
- 2013-10-22 US US14/437,251 patent/US9409901B2/en not_active Expired - Fee Related
- 2013-10-22 AU AU2013334860A patent/AU2013334860B2/en not_active Ceased
- 2013-10-22 WO PCT/US2013/066041 patent/WO2014066304A1/en not_active Ceased
-
2015
- 2015-04-21 IL IL238415A patent/IL238415B/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008006790A1 (en) * | 2006-07-14 | 2008-01-17 | Glaxo Group Limited | Indole compounds |
| WO2008006793A1 (en) * | 2006-07-14 | 2008-01-17 | Glaxo Group Limited | Indole compounds |
| WO2012006068A2 (en) * | 2010-06-28 | 2012-01-12 | President And Fellows Of Harvard College | Compounds for the inhibition of cellular proliferation |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015534990A (ja) | 2015-12-07 |
| IL238415A0 (en) | 2015-06-30 |
| US9409901B2 (en) | 2016-08-09 |
| IL238415B (en) | 2018-04-30 |
| AU2013334860A1 (en) | 2015-05-14 |
| WO2014066304A1 (en) | 2014-05-01 |
| EP2909203A1 (en) | 2015-08-26 |
| US20150274717A1 (en) | 2015-10-01 |
| EP2909203A4 (en) | 2016-04-06 |
| CA2888889A1 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7416872B2 (ja) | 癌の治療のための配合剤 | |
| US9409901B2 (en) | Compositions and methods for treating or preventing diseases or disorders associated with misregulated EIF4E | |
| EA025033B1 (ru) | Диаминиевые соли фенотиазина и их применение | |
| US20180022735A1 (en) | Modulators of the p70s6 kinase for use in the treatment of brain disorders and triple-negative breast cancer | |
| JP2022524398A (ja) | 化合物の製剤およびそれらの使用 | |
| TW202228716A (zh) | 賽洛西賓(psilocybin)之氘化衍生物及其用途 | |
| TW201829365A (zh) | 苯甲酸鈉之同素異形體形式及其用途 | |
| WO2018175537A1 (en) | Selective inhibition of gluconeogenic activity | |
| US10098861B1 (en) | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof | |
| KR102927199B1 (ko) | 기분장애를 위한 신규한 감마 아미노부티르산 타입 a 수용체 모듈레이터 | |
| WO2014183673A1 (zh) | 阿那格雷及其衍生物的抗肿瘤用途 | |
| EP3356348A1 (en) | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors | |
| EP3502102A1 (en) | Sting inhibitors | |
| TW202023564A (zh) | 以吡唑并［3，4 - d］嘧啶化合物為有效成分之治療劑 | |
| US12042493B2 (en) | Pharmaceutical compounds for use in treating Huntington's disease | |
| KR20130064162A (ko) | 암의 증식, 재발 또는 전이 억제용 의약 조성물 | |
| EA017817B1 (ru) | 3-АРИЛСУЛЬФОНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| EP4079306A1 (en) | Therapeutic agent containing fused pyrimidine compound as active ingredient | |
| EP4083044A1 (en) | Use of triazolotriazine derivative in treatment of diseases | |
| WO2025055868A1 (zh) | 抑制cdk4/6与细胞周期蛋白d的蛋白-蛋白相互作用的化合物 | |
| HK40073574A (en) | Therapeutic agent containing fused pyrimidine compound as active ingredient | |
| WO2026068852A1 (en) | N-substituted 9-aminoacridines and their use in the treatment of cancer | |
| CN122055154A (zh) | 组合疗法 | |
| HK40067960A (en) | Therapeutic or prophylactic method for diabetes using combination medicine | |
| HU230633B1 (hu) | Hő sokk protein (HSP) ko-inducer sajátosságot mutató vegyület alkalmazása 2-es típusú cukorbetegség kezelésében inzulinérzékenyítő hatás fokozására |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: BANTAM PHARMACEUTICAL, LLC Free format text: FORMER APPLICANT(S): EGENIX, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |